Rinomaris Nazal Spray. 0.05% 15ml vial

Description

Composition
Active substance:
1 ml contains: 0.500 mg Xylometazoline hydrochloride.
Excipients:
Adriatic Sea Water 251 mg Potassium dihydrogen phosphate 0.502 mg purified water ad 1 ml.
Description:
A colorless, transparent solution was odorless.
Product form:
Nasal spray, 0.05%.
10 ml 15 ml of the product in a plastic bottle fitted with a spray device and a protective cover from propylene. One vial with instructions for use placed in a cardboard box.
Contraindications
Arterial hypertension, tachycardia expressed arteriosclerosis, glaucoma, atrophic rhinitis, thyrotoxicosis, surgical interventions in the meninges (history), children under 2 years of age, sensitivity to the drug.
Used with caution in patients with diabetes mellitus, angina pectoris (CHD).
Dosage
0.5 mg / ml
Indications
Acute respiratory illness with symptoms of rhinitis (common cold).
Allergic rhinitis (hay fever).
Sinusitis.
Evstahiit.
Otitis media (to minimize swelling of nasal mucosa).
Preparing the patient for diagnostic procedures in the nasal passages.
Interaction with other drugs
Incompatible with MAO inhibitors and tricyclic antidepressants.
Overdose
Symptoms: increased side effects.
Treatment: symptomatic therapy.
pharmachologic effect
Pharmacological group:
Decongestant agent – vasoconstrictor (alpha-agonists).
Pharmacological properties:
Rinomaris®- preparation for intranasal application.
Xylometazoline has alpha adrenomimeticheskim action: causes vasoconstriction of nasal mucosa, thereby eliminating, edema and hyperemia of the mucosa of the nasopharynx. Relieves nasal breathing in rhinitis. At therapeutic concentrations does not irritate, does not cause flushing. Effect occurs within a few minutes after application and lasts for 12 hours.
Sterilized sea water, part of the drug Rinomaris®, it helps to maintain normal physiological condition of nasal mucosa, liquefaction of mucus and normalization of its production of goblet cells in the nasal mucosa.
Trace elements improve the function of the ciliated epithelium, thus reducing the adverse local reactions such as irritation and / or dryness of the nasal mucosa.
Pharmacokinetics:
When applied topically, practically not absorbed, the plasma concentrations are so small that they can not identify with modern analytical methods.
Pregnancy and breast-feeding
During pregnancy and lactation formulation should be applied only after careful assessment of the risk-benefit ratio for the mother and fetus is not allowed exceeding the recommended doses.
Conditions of supply of pharmacies
Without recipe.
side effects
With frequent and / or prolonged use – irritation and / or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion, edema of the nasal mucosa.
Palpitations, tachycardia, arrhythmias, increased blood pressure, headache, vomiting, insomnia, blurred vision; during prolonged use at high doses – depression.
special instructions
Before use, clean the nasal passages.
Rinomaris® not be used for a long time, for example, in chronic rhinitis.
Effects on ability to drive vehicles and management mechanisms.
Xylometazoline at doses exceeding recommended, may affect the ability to operate vehicles or equipment.
Storage conditions
Store at a temperature not higher than 25 ° C in the reach of children.
Dosing and Administration
Children aged 2 to 6 years of 1 injection per nostril 1-2 times a day;
Children aged 6 years and 1 injection in each nostril 2-3 times a day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist